PYXIS ONCOLOGY INC. - COMMON STOCK

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

25 Apr 2025 13:17:47 By Nasdaq GlobeNewswire

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

02 Apr 2025 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

25 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

18 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

03 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

26 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

04 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

19 Dec 2024 16:08:10 By Nasdaq GlobeNewswire

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

20 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

12 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

11 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

29 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

14 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

29 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 Jun 2024 16:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

10 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

30 May 2024 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

14 May 2024 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 Mar 2024 16:30:00 By Nasdaq GlobeNewswire